癌症患者尿路源性菌血症的多重耐药与复发特征
BACKGROUND: Urinary tract infections (UTI) in oncological patients can lead to bacteraemia (bUTI), increasing morbidity and mortality. This study assessed the characteristics, outcomes and recurrence of bUTI in oncological patients.…
要点
- 癌症患者尿路源性菌血症以革兰阴性杆菌为主,多重耐药株占19.6%。
- 23.4%病例接受不恰当经验性抗生素治疗,复发率14.0%。
核心结论
- 癌症患者尿路源性菌血症主要由革兰阴性杆菌引起,多重耐药分离株比例高且死亡率高。
- 不恰当经验性抗生素治疗常见,复发显著,需针对性预防策略和优化经验性治疗。
研究设计与样本
- 回顾性队列研究,2008至2019年在巴塞罗那Hospital Clinic开展。
- 共分析478例癌症患者的561次尿路源性菌血症发作。
主要发现
- 革兰阴性杆菌引起87.3%发作,大肠埃希菌和克雷伯菌属最常见。
- 多重耐药革兰阴性杆菌引起19.6%发作,23.4%病例接受不恰当经验性抗生素治疗。
- 14.0%患者出现复发性尿路源性菌血症,简单预测评分可有效识别高复发风险患者。
- 无发热、感染性休克和产碳青霉烯酶肠杆菌与较高相关死亡率有关。
关键数值与推荐
- 泌尿系统肿瘤累及占62.2%,59.4%有泌尿器械操作。
- 63.8%报告既往因尿路感染住院但无菌血症。
- 菌血症后47%癌症治疗延迟,33.6%停止。
临床怎么用
- 对癌症患者尿路源性菌血症应警惕多重耐药革兰阴性杆菌,优化经验性抗生素选择以减少不恰当治疗。
- 可利用简单预测评分识别高复发风险患者,加强预防策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Urinary tract infections (UTI) in oncological patients can lead to bacteraemia (bUTI), increasing morbidity and mortality. This study assessed the characteristics, outcomes and recurrence of bUTI in oncological patients. METHODS: A retrospective cohort study was conducted at Hospital Clinic, Barcelona, from 2008 to 2019. All episodes of bUTI in oncological patients were analysed. Multivariable regression models identified independent risk factors for multidrug-resistant (MDR) Gram-negative bacilli (GNB), recurrent bUTI and related mortality. RESULTS: A total of 561 bUTI episodes were identified in 478 oncological patients. Urinary tract involvement due to neoplasm was present in 62.2%, and 59.4% had urinary tract instrumentation. Prior UTI-related admission without bacteraemia was reported in 63.8%. Following bUTI, oncological treatment was delayed in 47% and stopped in 33.6% of cases. GNB caused 87.3% of episodes, with Escherichia coli and Klebsiella spp. being the most common pathogens. Enterococcus spp. and Pseudomonas aeruginosa were frequent, particularly in patients with urinary instrumentation. MDR-GNB caused 19.6% of episodes, and 23.4% of cases received inappropriate empirical antibiotic therapy (IEAT). Recurrent bUTI occurred in 14.0% of patients. A simple predictive score efficiently identified patients at high risk of recurrence. Thirty-day mortality was 15.3%, and bUTI-related mortality was 10.7%, with absence of fever, septic shock and carbapenemase-producing Enterobacterales linked to higher related mortality. CONCLUSION: bUTI in oncological patients is predominantly caused by GNB, with high rates of MDR isolates and high mortality. IEAT is common, and recurrence is significant, highlighting the need for targeted preventive strategies and optimized empirical therapy.
引用
- Grafia I, Moll-Febrer A, Santillán SJ, et al. Multidrug resistance and recurrence in urinary bacteraemia among cancer patients. J Antimicrob Chemother. 2025. PMID: 40973136. doi:10.1093/jac/dkaf335
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。